| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 06/30/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
35 |
| 06/24/20 | 8-K | Current report filing |
|
3 | |
| 06/12/20 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
123 | |
| 06/11/20 | EFFECT | Notice of Effectiveness |
|
1 | |
| 06/11/20 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
84 | |
| 06/09/20 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 06/09/20 | UPLOAD | SEC-generated letter |
|
1 | |
| 06/04/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 06/03/20 | S-1 | General form of registration statement for all companies including face-amount certificate companies |
|
|
233 |
| 05/26/20 | DEF 14A | Definitive proxy statements |
|
36 |
Lexaria Bioscience Corp.
Lexaria Bioscience Corp.